GENKYOTEX ANNOUNCES COMPLETION OF 24-WEEK TREATMENT PERIOD OF ITS PHASE 2 TRIAL WITH GKT831 IN PRIMARY BILIARY CHOLANGITIS

GENKYOTEX ANNOUNCES COMPLETION OF 24-WEEK TREATMENT PERIOD OF ITS PHASE 2 TRIAL WITH GKT831 IN PRIMARY BILIARY CHOLANGITIS

  • Top line results expected in spring 2019
  • GKT 831 exhibited a favorable safety profile throughout the study
  • No drop outs or treatment interruptions due to pruritus
  • 2 SAEs recorded in the study, both unrelated to GKT831

 

Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the last patient has completed on March 8, 2019 the full 24-week treatment in its Phase 2 trial of GKT831 in patients with Primary Biliary Cholangitis (PBC). Positive interim efficacy results after 6 weeks of treatment were previously announced in November 2018. Final results are expected in the spring of 2019. Importantly, final results will include fibrosis and quality of life endpoints.

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2019/PR_Genkyotex_Last-Patient-treated-EN_2d89a.pdf